Immunotherapy in hepatocellular carcinoma

Research output: Contribution to journalReview article

Abstract

Hepatocellular carcinoma (HCC) is considered an immunogenic tumor that arises in chronically inflamed livers due to underlying chronic liver disease caused by viral and non-viral pathogenesis. This inflammation leads to tumor development and is associated to higher tumor immunogenicity. For this reason immunotherapeutic approaches may be suitable therapeutic strategies for HCC. Indeed, several preclinical and clinical data support this hypothesis showing that immunotherapy and even more their combination may be a good alternative candidate for the treatment of HCC patients. However, considering that the liver plays a central role in host defense as well as in the maintenance of self-tolerance, it is characterized by a strong intrinsic immune suppressive microenvironment as well as by a high immune evasion, which may represent a major impediment for an effective immune response against tumor. Furthermore, the low expression of tumor antigens on liver cancer cells leads to a lower T-cell activation and tumor infiltration, resulting in a less efficient control of the tumor growth and, consequently, in a worse clinical outcome. For this reason, strategies should be developed to counteract the different factors in the HCC tumor microenvironment playing a major role in reducing the effects of immunotherapy.

Original languageEnglish
Pages (from-to)291-297
Number of pages7
JournalAnnals of Hepatology
Volume18
Issue number2
DOIs
Publication statusPublished - Mar 1 2019

Fingerprint

Immunotherapy
Hepatocellular Carcinoma
Neoplasms
Immune Evasion
Self Tolerance
Tumor Microenvironment
Liver
Neoplasm Antigens
Liver Neoplasms
Liver Diseases
Chronic Disease
Inflammation
T-Lymphocytes
Therapeutics
Growth

ASJC Scopus subject areas

  • Hepatology

Cite this

Immunotherapy in hepatocellular carcinoma. / Buonaguro, Luigi; Mauriello, Angela; Cavalluzzo, Beatrice; Petrizzo, Annacarmen; Tagliamonte, Maria.

In: Annals of Hepatology, Vol. 18, No. 2, 01.03.2019, p. 291-297.

Research output: Contribution to journalReview article

@article{3afd1677af844722a8ce0f0adde5c494,
title = "Immunotherapy in hepatocellular carcinoma",
abstract = "Hepatocellular carcinoma (HCC) is considered an immunogenic tumor that arises in chronically inflamed livers due to underlying chronic liver disease caused by viral and non-viral pathogenesis. This inflammation leads to tumor development and is associated to higher tumor immunogenicity. For this reason immunotherapeutic approaches may be suitable therapeutic strategies for HCC. Indeed, several preclinical and clinical data support this hypothesis showing that immunotherapy and even more their combination may be a good alternative candidate for the treatment of HCC patients. However, considering that the liver plays a central role in host defense as well as in the maintenance of self-tolerance, it is characterized by a strong intrinsic immune suppressive microenvironment as well as by a high immune evasion, which may represent a major impediment for an effective immune response against tumor. Furthermore, the low expression of tumor antigens on liver cancer cells leads to a lower T-cell activation and tumor infiltration, resulting in a less efficient control of the tumor growth and, consequently, in a worse clinical outcome. For this reason, strategies should be developed to counteract the different factors in the HCC tumor microenvironment playing a major role in reducing the effects of immunotherapy.",
author = "Luigi Buonaguro and Angela Mauriello and Beatrice Cavalluzzo and Annacarmen Petrizzo and Maria Tagliamonte",
year = "2019",
month = "3",
day = "1",
doi = "10.1016/j.aohep.2019.04.003",
language = "English",
volume = "18",
pages = "291--297",
journal = "Annals of Hepatology",
issn = "1665-2681",
publisher = "Mexican Association of Hepatology",
number = "2",

}

TY - JOUR

T1 - Immunotherapy in hepatocellular carcinoma

AU - Buonaguro, Luigi

AU - Mauriello, Angela

AU - Cavalluzzo, Beatrice

AU - Petrizzo, Annacarmen

AU - Tagliamonte, Maria

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Hepatocellular carcinoma (HCC) is considered an immunogenic tumor that arises in chronically inflamed livers due to underlying chronic liver disease caused by viral and non-viral pathogenesis. This inflammation leads to tumor development and is associated to higher tumor immunogenicity. For this reason immunotherapeutic approaches may be suitable therapeutic strategies for HCC. Indeed, several preclinical and clinical data support this hypothesis showing that immunotherapy and even more their combination may be a good alternative candidate for the treatment of HCC patients. However, considering that the liver plays a central role in host defense as well as in the maintenance of self-tolerance, it is characterized by a strong intrinsic immune suppressive microenvironment as well as by a high immune evasion, which may represent a major impediment for an effective immune response against tumor. Furthermore, the low expression of tumor antigens on liver cancer cells leads to a lower T-cell activation and tumor infiltration, resulting in a less efficient control of the tumor growth and, consequently, in a worse clinical outcome. For this reason, strategies should be developed to counteract the different factors in the HCC tumor microenvironment playing a major role in reducing the effects of immunotherapy.

AB - Hepatocellular carcinoma (HCC) is considered an immunogenic tumor that arises in chronically inflamed livers due to underlying chronic liver disease caused by viral and non-viral pathogenesis. This inflammation leads to tumor development and is associated to higher tumor immunogenicity. For this reason immunotherapeutic approaches may be suitable therapeutic strategies for HCC. Indeed, several preclinical and clinical data support this hypothesis showing that immunotherapy and even more their combination may be a good alternative candidate for the treatment of HCC patients. However, considering that the liver plays a central role in host defense as well as in the maintenance of self-tolerance, it is characterized by a strong intrinsic immune suppressive microenvironment as well as by a high immune evasion, which may represent a major impediment for an effective immune response against tumor. Furthermore, the low expression of tumor antigens on liver cancer cells leads to a lower T-cell activation and tumor infiltration, resulting in a less efficient control of the tumor growth and, consequently, in a worse clinical outcome. For this reason, strategies should be developed to counteract the different factors in the HCC tumor microenvironment playing a major role in reducing the effects of immunotherapy.

UR - http://www.scopus.com/inward/record.url?scp=85066163543&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066163543&partnerID=8YFLogxK

U2 - 10.1016/j.aohep.2019.04.003

DO - 10.1016/j.aohep.2019.04.003

M3 - Review article

VL - 18

SP - 291

EP - 297

JO - Annals of Hepatology

JF - Annals of Hepatology

SN - 1665-2681

IS - 2

ER -